Interius BioTherapeutics

Interius BioTherapeutics, founded in 2019 and headquartered in the United States, is a pioneering biotechnology company with a compelling slogan: "Interius is developing new ways to engineer cells inside the human body, right where they live." This early-stage firm aims to revolutionize cell and gene therapy by leveraging cutting-edge delivery technology based on the groundbreaking inventions of Dr. Saar Gill from the University of Pennsylvania. The company operates in the biopharma, biotechnology, healthcare, and pharmaceutical industries. Interius recently secured a substantial $21.45M debt financing investment on 20 October 2023. While the specific investors involved in this recent round of financing were not disclosed, it is clear that this substantial investment underscores the potential and promise that Interius holds in the field of biotechnology and therapeutics.